Psoriatic Arthritis
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Clinical manifestations vary significantly between patients. It can present with oligoarticular joint involvement, typically asymmetric, or as a polyarticular disease affecting five or more joints, usually with an asymmetric distribution similar to rheumatoid arthritis.&nbsp;Psoriatic Arthritis (PsA) is a chronic, immune-mediated inflammatory disorder that primarily affects individuals with psoriasis, leading to joint pain, stiffness, swelling, and progressive joint damage if left untreated. It is a heterogeneous condition that can involve peripheral joints, the spine, and entheses, significantly impacting a patient&rsquo;s mobility and quality of life. Early diagnosis remains a challenge due to its overlap with other inflammatory arthropathies such as rheumatoid arthritis, making clinical awareness and biomarker development crucial for improved disease management.
&nbsp;
Psoriatic Arthritis Epidemiology Segmentation in the 7MM
<ul>
<li class="ql-align-justify">Total Prevalent Cases</li>
<li class="ql-align-justify">Total Diagnosed Cases</li>
<li class="ql-align-justify">Gender-specific Cases</li>
<li class="ql-align-justify">Age-specific Cases</li>
<li class="ql-align-justify">Severity-specific Cases </li>
</ul>
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/psoriatic-arthritis-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Psoriatic Arthritis Epidemiological Insights Observed in the 7MM</a> (2021)
The total number of incident cases of Psoriatic Arthritis observed in the 7MM was observed to be 1.5 million in the year 2021
The highest diagnosed Psoriatic Arthritis population accounting for 650K cases, was found in the United States, followed by EU5 (750K) and Japan (73K) in the year 2021.&nbsp;
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/psoriatic-arthritis-market" target="_blank" rel="noopener noreferrer">Psoriatic Arthritis Market Insight</a>
The market size of Psoriatic Arthritis in the 7MM was found to be approximately USD 9 million in 2021
&nbsp;
Psoriatic Arthritis Market Strengths
Increased prevalence, growth in awareness, and lifestyle changes have necessitated changes in the diagnosis and treatment of Psoriatic Arthritis in the recent decade.&nbsp;
&nbsp;
Psoriatic Arthritis Market Opportunities
The development of disease models might help in the understanding of the underlying mechanisms that contribute to the development of Psoriatic Arthritis.
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight" target="_blank" rel="noopener noreferrer">Psoriatic Arthritis Emerging Drugs and Key Companies</a>
<ul>
<li class="ql-align-justify">Bimekizumab: UCB Biopharma</li>
<li class="ql-align-justify">Tildrakizumab: Sun Pharmaceutical Industries Limited</li>
<li class="ql-align-justify">Deucravacitinib: BMS</li>
<li class="ql-align-justify">Izokibep: Affibody AB</li>
</ul>
The <a href="https://www.delveinsight.com/report-store/psoriatic-arthritis-market">Psoriatic Arthritis Market</a> has witnessed steady growth in recent years, driven by increasing disease prevalence, improved diagnostic rates, and the expanding adoption of advanced biologic and targeted synthetic therapies. Rising awareness among healthcare professionals and patients has further contributed to earlier treatment initiation, thereby improving disease outcomes. The market is also supported by robust research and development activities focusing on next-generation immunomodulators and precision medicine approaches. Key pharmaceutical players are actively investing in pipeline expansion, aiming to address unmet needs such as treatment resistance and long-term disease control.
Treatment for Psoriatic Arthritis has evolved significantly from conventional disease-modifying antirheumatic drugs (DMARDs) to highly effective biologics and Janus kinase (JAK) inhibitors. Biologics targeting tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 pathways have demonstrated strong efficacy in reducing both joint and skin symptoms. In addition, JAK inhibitors offer oral alternatives that improve patient compliance and convenience. Despite these advancements, a proportion of patients still experience inadequate response or relapse, highlighting the need for more durable and safer therapies.
Overall, the Psoriatic Arthritis landscape is rapidly transforming, with ongoing clinical trials and emerging therapies expected to further enhance treatment outcomes. Continued innovation, coupled with early diagnosis and personalized treatment strategies, is anticipated to drive sustained growth in the Psoriatic Arthritis market in the coming years.

Psoriatic Arthritis Market

Psoriatic Arthritis Market Infographics

Psoriatic Arthritis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape.